AB Active ETFs Inc - AB Corporate Bond ETF
EYEG
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.51M
Close$
$2.03
93.9% downside
Current Fair Value
93.9% downsideOvervalued by 93.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $25.51 Million |
|---|---|
| Enterprise Value | $20.02 Million |
| Dividend Yield | $1.71 (4.74%) |
| Earnings per Share | $-2.64 |
| Beta | 0.21 |
| Outstanding Shares | 6,177,679 |
Return
| Return on Equity | -65.18% |
|---|---|
| Return on Assets | -46.21% |
| Return on Invested Capital | 22.08% |
Valuation & Multiples
| P/E Ratio | -13.31 |
|---|---|
| PEG | 390 |
| Price to Sales | - |
| Price to Book Ratio | 16.64 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 4.24 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 8, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eyegate Pharmaceuticals Inc
CEO: Stephen From